Osteorise

Osteorise Indications/Uses

risedronic acid

Manufacturer:

CCL Pharma

Distributor:

Manawhari
Full Prescribing Info
Indications/Uses
Postmenopausal Osteoporosis: Risedronate Sodium (Osteorise) is indicated for the treatment and prevention of osteoporosis in postmenopausal women.
Treatment of Osteoporosis: In postmenopausal women with osteoporosis, Risedronate Sodium (Osteorise) increases BMD and reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures. Osteoporosis may be confirmed by the presence or history of osteoporotic fracture, or by the finding of low bone mass.
Prevention of Osteoporosis: Risedronate Sodium (Osteorise) may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of fracture.
Glucocorticoid-Induced Osteoporosis: Risedronate Sodium (Osteorise) is indicated for the prevention and treatment of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage equivalent to 7.5 mg or greater of prednisone) for chronic diseases. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D.
Paget's Disease: Risedronate Sodium (Osteorise) is indicated for treatment of Paget's disease of bone (osteitis deformans) (1) who have a level of serum alkaline phosphatase at least 2 times the upper limit of normal, or (2) who are symptomatic, or (3) who are at risk for future complications from their disease, to induce remission (normalization of serum alkaline phosphatase).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in